Drugs / BVT.115959
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00452777 | May → Dec 2007 | diabetic polyneuropathy | Swedish Orphan Biovitrum | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2008-04-07 | Sobi, Inc. | Results Biovitrum's unique neuropathic pain compound is very safe and showspositive effect sobi.com ↗
The results of this first patient study is promising as it shows a high level of safety and tolerability, as well as a positive treatment effect that increased over time. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-04-07 | Sobi, Inc. | Biovitrum's unique neuropathic pain compound is very safe and showspositive effect sobi.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BVT.115959 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00452777 ↗ |
| Known as | Spongosine | ChEMBL registry synonym — accepted as the source's own label CHEMBL470888 ↗ |
| Action | Activate | “BVT.115959, a Novel A2A Agonist” NCT00452777 ↗1“Adenosine A2a receptor agonist” CHEMBL470888 ↗ |
| Modality | Small molecule | — CHEMBL470888 ↗ |
| Route | Oral | “administered orally” NCT00452777 ↗ |
| Target | ADORA2A | “Adenosine A2a receptor agonist” CHEMBL470888 ↗ |